Skip to main content

The Front Row lecture series: Giordano Lippi, PhD

Wednesday, September 09, 2026

4:00-6:00 PM PT

Department of Neuroscience

Share

Add to Calendar:

Micro molecules, big impact: New approaches to neurodevelopmental disorders

The human brain depends on remarkable precision. As neurons develop, they must produce the right proteins at the right place and time to build the complex networks that drive thought, learning and behavior. In this free Front Row lecture, Scripps Research associate professor Giordano Lippi will explore how tiny molecules called microRNAs help control this process. His research has revealed that microRNAs regulate many genes linked to neurodevelopmental disorders, including severe intellectual disability and epilepsy. Discover how Lippi’s team is developing new tools to restore protein production in disease-causing genes, opening new possibilities for understanding and potentially treating genetic disorders of the developing brain.

About the Front Row lecture series

Whether you’re a science enthusiast or a lifelong learner, our Front Row lecture series is designed for you. From protein “choreography” to immune system-boosting sugars to regenerative medicines, learn about the trailblazing discoveries at Scripps Research that could transform human health. Tune in virtually along with thousands around the world, or join us in person in La Jolla, California. 

The Front Row experience… science so close, it’s personal.
Learn more at frontrow.scripps.edu.

More to explore
Precision immunotherapy: How “switchable” CAR-Ts work in cancer and autoimmune diseases
Video

Precision immunotherapy: How “switchable” CAR-Ts work in cancer and autoimmune diseases

What if we could control powerful CAR-T cell therapies like flipping a switch? At the Calibr-Skaggs Institute for Innovative Medicines at Scripps Research, we're pioneering a next-generation "switchable" CAR-T (sCAR-T) platform—designed to tackle cancer and autoimmune diseases with greater precision, safety and durability. Traditional CAR-T has been highly successful, but multiple barriers remain: off-target toxicity, T-cell ‘exhaustion’ (weakening of CAR-T cell response over time), and manufacturing challenges restrict the widespread use and application of traditional CAR-T to solid tumors. Our platform features a universal design with antibody-based “switches” that are selective for multiple disease-related targets—increasing specificity while reducing potential off-target effects. Preliminary results from our phase 1 trial in B-cell malignancies are promising, and we're now gearing up to expand into solid tumors and autoimmune conditions. Watch to see how this innovative approach could transform the future of immunotherapy.

Calibr-Skaggs Drug Discovery Autoimmune Diseases Cancer
Scripps Research scientists honored with prestigious CZI awards to address diseases tied to aging
News

Scripps Research scientists honored with prestigious CZI awards to address diseases tied to aging

Christopher Parker and Giordano Lippi are unraveling the metabolic and protein mechanisms, respectively, that go awry in aging and disease—including Alzheimer’s.

Whitehall Foundation honors two pioneering Scripps Research scientists
News

Whitehall Foundation honors two pioneering Scripps Research scientists

Neuroscientists Giordano Lippi and Li Ye have received grants from the Whitehall Foundation to support their studies into brain function.

Event background

The Front Row lecture series: Ryan Shenvi, PhD

Wednesday, August 19, 2026

4:00 - 6:00 PM PT

Enter curious, leave informed.

Event background

The Front Row lecture series: Christian Diercks, PhD

Wednesday, October 14, 2026

4:00 - 6:00 PM PT

Enter curious, leave informed.

Event background

The Front Row lecture series: Darrell Irvine, PhD

Wednesday, November 18, 2026

4:00 - 6:00 PM PT

Enter curious, leave informed.

Groundbreaking Science.
Life-changing Medicine.